Fulcrum Therapeutics
Fulcrum Therapeutics' revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$60 million. The diluted share count rose 2.2%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Fulcrum Therapeutics does
Fulcrum Therapeutics is a clinical-stage drug company, so it has no approved products. It develops small-molecule medicines for rare diseases with a known genetic cause.
Its lead product candidate is pociredir, a pill designed to raise fetal hemoglobin, a form of the oxygen-carrying protein that is normally made before birth, as a treatment for sickle cell disease. It has finished dosing in a Phase 1b trial called PIONEER in adults with the disease and says it saw increases in fetal hemoglobin and improvements in markers of anemia and red blood cell breakdown. It is starting an open-label extension trial to study longer-term safety.
The company also uses a discovery approach to find drug targets that control gene activity. It presented preclinical data on FTX-6274, a prostate cancer candidate, in 2025. It decided not to advance its program for bone marrow failure syndromes and will focus on pociredir and its blood disorder programs.
Its biggest risks, as it describes them
- Losses since its start, and a need for substantial additional funding.
- It has only one product candidate in clinical trials, so its success depends on pociredir.
- Serious side effects found in its drugs, or in others' drugs of the same class, could stop development.
- It relies on contract manufacturers to make its drug candidates.
Income statement
Fulcrum Therapeutics lost money in fiscal 2025: a net loss of $75 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 35 | 35 | 26 | 58 | 198 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 11.8x | 12.4x | 17.7x | 22.6x | 27.4x |
| Quick ratio | 11.8x | 12.4x | 17.7x | 22.6x | 27.4x |
Cash flow
Projections
Project Fulcrum Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $1.5 million of Fulcrum Therapeutics shares on the open market, and 4 insiders sold $58.8 million, $449,150 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 17, 2026 | Kevin Tang10% owner | Bought | 50,945 | $3.52 | $179,326 | Form 4 |
| Jul 16, 2026 | Kevin Tang10% owner | Bought | 116,671 | $3.56 | $415,349 | Form 4 |
| Jul 15, 2026 | Tang Capital Management Llc10% owner | Bought | 107,377 | $3.56 | $382,262 | Form 4 |
| Jul 14, 2026 | Tang Capital Management Llc10% owner | Bought | 129,603 | $3.57 | $462,906 | Form 4 |
| Jul 13, 2026 | Tang Capital Management Llc10% owner | Bought | 12,966 | $3.54 | $45,900 | Form 4 |
| Jun 26, 2026 | Alan EzekowitzDirector | Sold plan | 18,000 | $3.65 | $65,700 | Form 4 |
| Feb 2, 2026 | Robert J GouldDirector | Sold plan | 15,000 | $10.72 | $160,800 | Form 4 |
| Jan 2, 2026 | Robert J GouldDirector | Sold plan | 15,000 | $11.87 | $178,050 | Form 4 |
| Dec 15, 2025 | Curtis Gale OltmansChief Legal Officer | Sold plan | 3,452 | $12.92 | $44,600 | Form 4 |
| Dec 8, 2025 | RA Capital Healthcare Fund LP10% owner | Sold | 4,175,139 | $13.98 | $58.4 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −3,316.8% | 2,748.9% | — |
| Altman Z'' | 7.46 | 13.38 | 20.53 |
| Accruals ratio | −2.6% | −2.9% | −4.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | — | — | — |
Compare
Put Fulcrum Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics | FY25 | −100.0% | — | — | — | — | — | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | 9 | 19 | 6 | 3 | 80 | 0 |
| Revenue growth | — | — | — | 117.2% | −66.9% | −55.8% | 2,752.1% | −100.0% |
| Gross profit | — | — | — | — | — | — | — | — |
| Research and development | 25 | 71 | 59 | 70 | 77 | 72 | 63 | 56 |
| Operating income | −34 | −84 | −72 | −81 | −113 | −111 | −22 | −85 |
| Net income | −33 | −83 | −71 | −81 | −110 | −97 | −10 | −75 |
| Diluted EPS (US$) | −31.14 | −8.13 | −2.79 | −2.29 | −2.44 | −1.59 | −0.16 | −1.18 |
| Diluted shares (millions) | 1 | 11 | 25 | 35 | 45 | 61 | 62 | 63 |
| Cash flow | ||||||||
| Cash from operations | −23 | −40 | −54 | −78 | −97 | −91 | −2 | −60 |
| Capital expenditure | 9 | 1 | 1 | 2 | 2 | 0 | 0 | 0 |
| Free cash flow | −32 | −40 | −55 | −80 | −99 | −91 | −2 | −60 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 4 | 7 | 11 | 13 | 15 | 15 | 12 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 73 | 97 | 57 | 35 | 35 | 26 | 58 | 198 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — |
| Total assets | 86 | 110 | 130 | 235 | 227 | 258 | 261 | 366 |
| Total liabilities | 10 | 23 | 34 | 24 | 28 | 22 | 18 | 17 |
| Shareholders' equity | −64 | 87 | 95 | 212 | 199 | 235 | 243 | 349 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | −811.6% | −423.0% | −1,774.8% | −3,945.2% | −27.4% | — |
| Net margin | — | — | −802.7% | −421.9% | −1,732.4% | −3,470.1% | −12.2% | — |
| Free cash flow margin | — | — | −623.3% | −418.5% | −1,561.2% | −3,261.1% | −3.1% | — |
| Rule of 40 (growth + FCF margin) | — | — | — | −301.3% | −1,628.1% | −3,316.8% | 2,748.9% | — |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | −704.1% | −77.7% | −52.7% | −53.5% | −44.8% | −4.1% | −25.3% |
| Return on assets | — | −84.3% | −59.0% | −44.4% | −47.6% | −40.2% | −3.8% | −23.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |